Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

Leukemia Research

Volumn 38, Issue 7, 2014, Pages 751-755

  Bally, Cecile ^a   Adès, Lionel ^a   Renneville, Aline ^b   Sebert, Marie ^a   Eclache, Virginie ^c   Preudhomme, Claude ^b   Mozziconacci, Marie Joelle ^d   de The, Hugues ^a,e   Lehmann Che, Jacqueline ^a,e   Fenaux, Pierre ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c Laboratoire d'Hématologie Assistance Publique HÔpitaux de Paris AP HP HÔpital Avicenne   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Acute myeloblastic leukemia; Azacitidine; Myelodysplastic syndromes; Prognostic factor; TP53 mutation

Indexed keywords

AZACITIDINE; PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHROMOSOME 5; CHROMOSOME 5Q; CHROMOSOME 7; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE MUTATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOSOMY; MONOSOMY 5; MONOSOMY 7; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TP53 GENE; TREATMENT RESPONSE;

ACUTE MYELOBLASTIC LEUKEMIA; AZACITIDINE; MYELODYSPLASTIC SYNDROMES; PROGNOSTIC FACTOR; TP53 MUTATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; FEMALE; GENES, P53; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 84902086132     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.03.012     Document Type: Article

References (29)

1. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
2. Shen L., Kantarjian H., Guo Y., Lin E., Shan J., Huang X., et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010, 28:605-613.
3. Itzykson R., Thepot S., Eclache V., Quesnel B., Dreyfus F., Beyne-Rauzy O., et al. Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine. Leukemia 2011, 25:1207-1209.
4. Itzykson R., Thépot S., Quesnel B., Dreyfus F., Beyne-Rauzy O., Turlure P., et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011, 117:403-411.
5. Lamarque M., Raynaud S., Itzykson R., Thepot S., Quesnel B., Dreyfus F., et al. The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience. Blood 2012, 120:5084-5085.
6. Itzykson R., Kosmider O., Cluzeau T., Mansat-De Mas V., Dreyfus F., Beyne-Rauzy O., et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011, 25:1147-1152.
7. Traina F., Jankowska A.M., Visconte V., Sugimoto Y., Szpurka H., Makishima H., et al. Impact of molecular mutations on treatment response to hypomethylating agents in MDS. ASH Annual Meeting Abstracts, vol. 118 2011, 461.
8. Jonveaux P., Fenaux P., Quiquandon I., Pignon J.M., Laï J.L., Loucheux-Lefebvre M.H., et al. Mutations in the p53 gene in myelodysplastic syndromes. Oncogene 1991, 6:2243-2247.
9. Fenaux P., Preudhomme C., Quiquandon I., Jonveaux P., Laï J.L., Vanrumbeke M., et al. Mutations of the P53 gene in acute myeloid leukaemia. Br J Haematol 1992, 80:178-183.
10. Haferlach C., Dicker F., Herholz H., Schnittger S., Kern W., Haferlach T. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia 2008, 22:1539-1541.
11. Bejar R., Levine R., Ebert B.L. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 2011, 29:504-515.
12. Bejar R., Stevenson K., Abdel-Wahab O., Galili N., Nilsson B., Garcia-Manero G., et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011, 364:2496-2506.
13. Kulasekararaj A.G., Smith A.E., Mian S.A., Mohamedali A.M., Krishnamurthy P., Lea N.C., et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol 2013, 160:660-672.
14. Jädersten M., Saft L., Smith A., Kulasekararaj A., Pomplun S., Göhring G., et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 2011, 29:1971-1979.
15. Preudhomme C., Vanrumbeke M., Lai J.L., Lepelley P., Wattel E., Fenaux P. Inactivation of the p53 gene in leukemias and myelodysplastic syndrome (MDS) with 17p monosomy. Leukemia 1994, 8:2241-2242.
16. Lai J.L., Preudhomme C., Zandecki M., Flactif M., Vanrumbeke M., Lepelley P., et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations. Leukemia 1995, 9:370-381.
17. Soenen V., Preudhomme C., Roumier C., Daudignon A., Laï J.L., Fenaux P. 17p deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ. Blood 1998, 91:1008-1015.
18. Wattel E., Preudhomme C., Hecquet B., Vanrumbeke M., Quesnel B., Dervite I., et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994, 84:3148-3157.
19. Flaman J.M., Frebourg T., Moreau V., Charbonnier F., Martin C., Chappuis P., et al. A simple P53 functional assay for screening cell lines, blood, and tumors. PNAS 1995, 92:3963-3967.
20. Manié E., Vincent-Salomon A., Lehmann-Che J., Pierron G., Turpin E., Warcoin M., et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res 2009, 69:663-671.
21. Kohlmann A., Klein H.-U., Weissmann S., Bresolin S., Chaplin T., Cuppens H., et al. The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories. Leukemia 2011, 25:1840-1848.
22. List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355:1456-1465.
23. Fenaux P., Giagounidis A., Selleslag D., Beyne-Rauzy O., Mufti G., Mittelman M., et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011, 118:3765-3776.
24. Kelaidi C., Park S., Sapena R., Beyne-Rauzy O., Coiteux V., Vey N., et al. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. Leukemia 2013, 27:1283-1290.
25. Oshiro M.M., Watts G.S., Wozniak R.J., Junk D.J., Munoz-Rodriguez J.L., Domann F.E., et al. Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression. Oncogene 2003, 22:3624-3634.
26. Nasr A.F., Nutini M., Palombo B., Guerra E., Alberti S. Mutations of TP53 induce loss of DNA methylation and amplification of the TROP1 gene. Oncogene 2003, 22:1668-1677.
27. Karpf A.R., Moore B.C., Ririe T.O., Jones D.A. Activation of the P53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine. Mol Pharmacol 2001, 59:751-757.
28. Ghanim V., Herrmann H., Heller G., Peter B., Hadzijusufovic E., Blatt K., et al. 5-Azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand. Blood 2012, 119:4242-4252.
29. Schnekenburger M., Grandjenette C., Ghelfi J., Karius T., Foliguet B., Dicato M., et al. Sustained exposure to the DNA demethylating agent, 2'-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy. Biochem Pharmacol 2011, 81:364-378.